| | | | | Madhav Kamat | | | mk@kamatpharma.com | | | Dr. Kamat is the Chief Executive Officer of Kamat Pharmatech. Dr. Kamat founded Kamat Pharmatech in 2013 after 27 years of working highly technical roles in pharmaceutical companies, most notably as Director of Manufacturing Technology of Sterile/Biological products at Bristol Myers Squibb.
Dr. Kamat is a recognized expert in the fields of lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. Following is a list of some products that Dr. Kamat was involved in development/launch/support:
- Biologicals: Yervoy, Nulojix IV, Orencia SC and IV, Erbitux, Remicade, Repro
- Small molecules: Ixempra, Tequin, Ketorolac, and Acyclovir
- Cytotoxics: Taxol, BicNu, Cytoxan, Carboplatin, Doxorubicin, Mutamycin, Etopophos
- Unique: Kenalog: Steroidal IM suspension product
Dr. Kamat serves as a registered pharmacist in the States of New Jersey and Pennsylvania.
Dr. Kamat also serves as a course director for "Lyophilization Technology" by CfPA in the US, Europe, and the rest of the world.
| | | | | | | | | | | | | “Formulation development of small and large volume parenterals”, M. S. Kamat and P. P. DeLuca. A book chapter, in Parenteral Medications, pages, 159-190, 2019. Published by CRC Press, Tayler and Francis Group. | | “Lyophilization Process Design and Development Using QbD Principles” in Quality by Design by Biopharmaceutical Drug Product Development, AAPS Advances in the Pharmaceutical Sciences Series 18, Chapter 14, pp 303-329, 2015 | | “Lyophilization Process Technology Transfer towards Product Launch”, Lyophilized Biologics and Vaccines, Chapter 18, pp 381-397, 2015. | | “Effect of the Dimension of Water Vapor Vent of Stopper in Lyophilization Process", PDA Journal of Pharmaceutical Sciences and Technology, December 2010. | | “In-situ, non-destructive and rapid monitoring of changes in protein stability as a function of various manufacturing conditions using Raman Spectroscopy”, American Pharmaceutical Review Journal, 2010. | | "Evaluation of Functional Equivalency among Lyophilizers as a Tool in Transfer of Lyophilization Cycles", Pharmaceutical Technology, Sept. 200 | | “Vacuum Decay Container Closure Integrity Testing Technology. Part 1. ASTM F2338 Precision and Bias Studies”. Published in PDA J. of Pharm. Sci. and Tech., Sept/Oct 2009. | | “Vacuum Decay Container Closure Integrity Testing Technology. Part 1 Comparison to Dye Ingress Tests”. Published in PDA J. of Pharm. Sci. and Tech., June/July/2009. | | Deluca P. P., Kamat M. S. and Koida Y., Acceleration of freeze dying cycles of aqueous solutions of lactose and sucrose with tertiary butyl alcohol, in Congr, of Int. Tech. Pharm., 1989, 1:439-437. | | Book Chapter: "Formulation development of an Antifibrin monoclonal antibody radiopharmaceutical", M. S. Kamat, G. L. Tolman, and J. M. Brown, in a Book titled, "Pharmaceutical Biotechnology, Vol. 9, pp: 343 64", (ed: Wang and Pearlman), 1996. | | "Near-Infrared spectroscopic determination of residual moisture in lyophilized sucrose through intact glass vials", M. S. Kamat, R. A. Lodder and P. P. DeLuca. Pharmaceutical Research, Vol., 11, 961-965, 1989. | | "Estimation of the degree of crystallinity in Cefazolin sodium by X-ray and IR methods", M. S. Kamat, P. P. DeLuca et al. Pharmaceutical Research, Vol. 5, 7, 421-425, 1988. | | "Hygroscopicity of Cefazolin sodium: Application to evaluate the crystallinity of freeze-dried product", T. Osawa, M. S. Kamat, and P. P. DeLuca, Pharmaceutical Research, Vol. 5, 7, 416-420, 1988. | | "Effect of solvent addition and thermal treatment on freeze-drying of Cefazolin sodium", Y. Koyama, M. S. Kamat, P. P. DeLuca et al, J. of Parenteral Sci. and tech., August, 1987. | | "Comparison of effects of ozone, cadmium chloride and carbon tetrachloride on [14C]antipyrine metabolism in conscious rats", Dutta S., Kamat M. Gole D., J-Appl-Toxicol. 1987 Apr; 7(2): 97-103. | | "Comparative bio-availability of tolbutamide and chlorpropamide in multiple dose study", M. S. Kamat et al. Indian Drugs 4, 13, 1982. | | "Bioavailability of Digoxin preparations by RIA methods", S. Vasavada, M. S, Kamat et al. Indian Drugs, 5, 14, 1983. |
| | | © 2024 Kamat Pharmatech.
All rights reserved. | |
|
|